Emtricitabine indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 6: | Line 6: | ||
EMTRIVA® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. | EMTRIVA® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. | ||
Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection. | Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection. | ||
EMTRIVA should not be coadministered with ATRIPLA®, COMPLERA®, STRIBILD™, TRUVADA®, or lamivudine-containing products. | EMTRIVA should not be coadministered with ATRIPLA®, COMPLERA®, STRIBILD™, TRUVADA®, or lamivudine-containing products. | ||
Revision as of 02:59, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
EMTRIVA® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection.
EMTRIVA should not be coadministered with ATRIPLA®, COMPLERA®, STRIBILD™, TRUVADA®, or lamivudine-containing products. In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history.[1]
References
Adapted from the FDA Package Insert.